![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Precipio Receives a CE-IVD Mark for its HemeScreen Diagnostic Reagents
Precipio Receives a CE-IVD Mark for its HemeScreen Diagnostic Reagents
Specialty cancer diagnostics company Precipio has received a CE-IVD mark for its HemeScreen reagents used in cancer-diagnosing test panels.
The reagents are approved for myeloproliferative neoplasms, acute myeloid leukemia, anemia/myelodysplastic syndromes and chronic lymphocytic leukemia. Together, those account for more than 70 percent of hematologic malignancies, the New Haven, Conn.-based company said.
Precipio CEO Ilan Danieli said the company will replicate its U.S. commercialization strategy of partnering with distributors in Europe and other markets that accept the CE-IVD mark.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct